Loading...

Sirona Biochem

TSXV:SBM
Snowflake Description

Weak fundamentals or lack of information.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
SBM
TSXV
CA$39M
Market Cap
  1. Home
  2. CA
  3. Pharmaceuticals & Biotech
Company description

Sirona Biochem Corp. operates as a cosmetic ingredient and drug discovery company in Canada and France. The last earnings update was 22 days ago. More info.


Add to Portfolio Compare Print
  • Sirona Biochem has significant price volatility in the past 3 months.
SBM Share Price and Events
7 Day Returns
-11.4%
TSXV:SBM
-2.4%
CA Biotechs
0.6%
CA Market
1 Year Returns
105.3%
TSXV:SBM
-1.1%
CA Biotechs
3.6%
CA Market
SBM Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Sirona Biochem (SBM) -11.4% 21.9% 178.6% 105.3% -9.3% 85.7%
CA Biotechs -2.4% 0% -1.9% -1.1% -3.2% -37.6%
CA Market 0.6% 1.9% 8.1% 3.6% 14.8% 6.7%
1 Year Return vs Industry and Market
  • SBM outperformed the Biotechs industry which returned -1.1% over the past year.
  • SBM outperformed the Market in Canada which returned 3.6% over the past year.
Price Volatility
SBM
Industry
5yr Volatility vs Market

SBM Value

 Is Sirona Biochem undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.

In this section, we usually try to help investors determine whether Sirona Biochem is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Sirona Biochem has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.

Show me the analysis anyway

INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Sirona Biochem. This is due to cash flow or dividend data being unavailable. The share price is CA$0.195.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Sirona Biochem's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Sirona Biochem's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
TSXV:SBM PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-01-31) in CAD CA$-0.01
TSXV:SBM Share Price ** TSXV (2019-04-18) in CAD CA$0.2
North America Biotechs Industry PE Ratio Median Figure of 38 Publicly-Listed Biotechs Companies 19.47x
Canada Market PE Ratio Median Figure of 554 Publicly-Listed Companies 15.17x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Sirona Biochem.

TSXV:SBM PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= TSXV:SBM Share Price ÷ EPS (both in CAD)

= 0.2 ÷ -0.01

-19.54x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Sirona Biochem is loss making, we can't compare its value to the North America Biotechs industry average.
  • Sirona Biochem is loss making, we can't compare the value of its earnings to the Canada market.
Price based on expected Growth
Does Sirona Biochem's expected growth come at a high price?
Raw Data
TSXV:SBM PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -19.54x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
North America Biotechs Industry PEG Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 1.43x
Canada Market PEG Ratio Median Figure of 254 Publicly-Listed Companies 1.22x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Sirona Biochem, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Sirona Biochem's assets?
Raw Data
TSXV:SBM PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-01-31) in CAD CA$-0.02
TSXV:SBM Share Price * TSXV (2019-04-18) in CAD CA$0.2
Canada Biotechs Industry PB Ratio Median Figure of 36 Publicly-Listed Biotechs Companies 4.82x
Canada Market PB Ratio Median Figure of 2,370 Publicly-Listed Companies 1.51x
TSXV:SBM PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= TSXV:SBM Share Price ÷ Book Value per Share (both in CAD)

= 0.2 ÷ -0.02

-12.39x

* Primary Listing of Sirona Biochem.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Sirona Biochem has negative assets, we can't compare the value of its assets to the CA Biotechs industry average.

Next steps:

  1. Take a look at our analysis of SBM’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Sirona Biochem's regulatory filings and announcements.
  3. Show me more potentially undervalued companies in the Biotechs industry
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Value checks
We assess Sirona Biochem's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Sirona Biochem has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

SBM Future Performance

 How is Sirona Biochem expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Sirona Biochem has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
23.4%
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Sirona Biochem expected to grow at an attractive rate?
  • Unable to compare Sirona Biochem's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Sirona Biochem's earnings growth to the Canada market average as no estimate data is available.
  • Unable to compare Sirona Biochem's revenue growth to the Canada market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
TSXV:SBM Future Growth Rates Data Sources
Data Point Source Value (per year)
Canada Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 23.4%
Canada Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 23.2%
Canada Market Earnings Growth Rate Market Cap Weighted Average 18.4%
Canada Market Revenue Growth Rate Market Cap Weighted Average 7.1%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
TSXV:SBM Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in CAD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
TSXV:SBM Future Estimates Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
TSXV:SBM Past Financials Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income *
2019-01-31 1 -1 -2
2018-10-31 1 -1 -1
2018-07-31 1 -1 -3
2018-04-30 1 -2 -4
2018-01-31 1 -2 -4
2017-10-31 0 -2 -4
2017-07-31 0 -3 -3
2017-04-30 0 -2 -3
2017-01-31 0 -2 -3
2016-10-31 0 -2 -3
2016-07-31 0 -2 -3
2016-04-30 0 -3 -3

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Sirona Biochem is high growth as no earnings estimate data is available.
  • Unable to determine if Sirona Biochem is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
TSXV:SBM Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Sirona Biochem Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

TSXV:SBM Future Estimates Data
Date (Data in CAD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
TSXV:SBM Past Financials Data
Date (Data in CAD Millions) EPS *
2019-01-31 -0.01
2018-10-31 -0.01
2018-07-31 -0.02
2018-04-30 -0.02
2018-01-31 -0.02
2017-10-31 -0.03
2017-07-31 -0.02
2017-04-30 -0.02
2017-01-31 -0.02
2016-10-31 -0.02
2016-07-31 -0.02
2016-04-30 -0.02

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Sirona Biochem will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Take a look at our analysis of SBM’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. Sirona Biochem's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. Sirona Biochem's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Sirona Biochem's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Canada market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Canada market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Sirona Biochem has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

SBM Past Performance

  How has Sirona Biochem performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Sirona Biochem's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Sirona Biochem does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Sirona Biochem's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Sirona Biochem's 1-year growth to the North America Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Sirona Biochem's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Sirona Biochem Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

TSXV:SBM Past Revenue, Cash Flow and Net Income Data
Date (Data in CAD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-01-31 0.78 -1.74 1.24 0.77
2018-10-31 1.28 -1.27 1.31 0.77
2018-07-31 1.15 -3.20 1.41 0.83
2018-04-30 0.57 -3.93 1.49 0.88
2018-01-31 0.57 -4.01 1.61 0.87
2017-10-31 0.01 -4.46 1.52 0.88
2017-07-31 -0.04 -2.78 1.66 0.90
2017-04-30 -0.03 -3.08 1.87 0.96
2017-01-31 0.36 -2.76 1.88 1.06
2016-10-31 0.36 -2.97 1.99 1.17
2016-07-31 0.41 -2.80 1.74 1.09
2016-04-30 0.40 -2.98 1.90 1.23
2016-01-31 0.01 -3.51 1.99 1.22
2015-10-31 0.01 -3.66 2.26 1.18
2015-07-31 -0.05 -3.45 2.35 1.02
2015-04-30 -0.05 -3.04 2.08 0.76
2015-01-31 0.15 -3.45 2.93 0.53
2014-10-31 0.21 -3.53 3.01 0.45
2014-07-31 0.26 -3.75 2.91 0.67
2014-04-30 0.26 -3.70 2.96 0.53
2014-01-31 0.06 -3.08 2.17 0.50
2013-10-31 -2.78 1.92 0.40
2013-07-31 -3.36 2.66 0.14
2013-04-30 -3.10 2.53 0.24
2013-01-31 -3.16 2.63 0.14
2012-10-31 -2.98 2.41 0.32
2012-07-31 -2.75 1.77 0.77
2012-04-30 -2.84 1.74 0.74

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Sirona Biochem has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
  • It is difficult to establish if Sirona Biochem has efficiently used its assets last year compared to the North America Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Sirona Biochem improved its use of capital last year versus 3 years ago (Return on Capital Employed) due to its liabilities exceeding its assets.
X
Past performance checks
We assess Sirona Biochem's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Sirona Biochem has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

SBM Health

 How is Sirona Biochem's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Sirona Biochem's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Sirona Biochem's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • Sirona Biochem's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of Sirona Biochem's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Sirona Biochem has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Sirona Biochem Company Filings, last reported 2 months ago.

TSXV:SBM Past Debt and Equity Data
Date (Data in CAD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-01-31 -2.83 2.51 0.06
2018-10-31 -2.26 2.51 0.34
2018-07-31 -2.37 3.00 0.58
2018-04-30 -2.49 2.73 0.16
2018-01-31 -2.05 2.71 0.70
2017-10-31 -2.04 2.69 0.27
2017-07-31 -0.14 2.21 0.09
2017-04-30 0.36 1.68 0.09
2017-01-31 1.00 1.20 0.33
2016-10-31 1.56 0.97 0.61
2016-07-31 2.07 0.98 0.94
2016-04-30 2.50 0.72 0.82
2016-01-31 2.36 0.92 1.09
2015-10-31 2.15 1.40 1.54
2015-07-31 1.78 1.39 0.88
2015-04-30 1.56 1.35 1.14
2015-01-31 1.07 1.39 0.72
2014-10-31 1.79 0.67 0.61
2014-07-31 1.64 0.57 0.34
2014-04-30 2.43 0.48 0.47
2014-01-31 2.18 0.51 0.63
2013-10-31 2.24 0.52 0.93
2013-07-31 1.75 0.51 0.51
2013-04-30 1.86 0.52 0.49
2013-01-31 1.39 0.43 0.09
2012-10-31 1.70 0.16 0.13
2012-07-31 2.41 0.05 0.55
2012-04-30 2.78 0.06 0.78
  • Sirona Biochem has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
  • Irrelevant to check if Sirona Biochem's debt level has increased considering it has negative shareholder equity.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Sirona Biochem has less than a year of cash runway based on current free cash flow.
  • Sirona Biochem has less than a year of cash runway if free cash flow continues to reduce at historical rates of -33.2% each year.
X
Financial health checks
We assess Sirona Biochem's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Sirona Biochem has a total score of 0/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

SBM Dividends

 What is Sirona Biochem's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Sirona Biochem dividends.
If you bought CA$2,000 of Sirona Biochem shares you are expected to receive CA$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Sirona Biochem's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Sirona Biochem's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
TSXV:SBM Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 20 Stocks 2.4%
Canada Market Average Dividend Yield Market Cap Weighted Average of 331 Stocks 3.5%
Canada Minimum Threshold Dividend Yield 10th Percentile 1.2%
Canada Bottom 25% Dividend Yield 25th Percentile 2%
Canada Top 25% Dividend Yield 75th Percentile 5.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

TSXV:SBM Future Dividends Estimate Data
Date (Data in CA$) Dividend per Share (annual) Avg. No. Analysts

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Sirona Biochem has not reported any payouts.
  • Unable to verify if Sirona Biochem's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Sirona Biochem's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Sirona Biochem has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Sirona Biochem's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.2%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Sirona Biochem afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Sirona Biochem has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

SBM Management

 What is the CEO of Sirona Biochem's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Howard Verrico
COMPENSATION CA$144,000
AGE 57
TENURE AS CEO 4.8 years
CEO Bio

Dr. Howard J. Verrico, M.D. is the Founder of Sirona Biochem Corp., has been Chief Executive Officer since June 18, 2014 and serves as its Secretary. Dr. Verrico served as the Chief Executive Officer of Sirona Biochem Corp. until October 2012 and its Interim President from December 16, 2011 to October 2012. He is a practicing physician working in both emergency and general practice in the province of British Columbia. He served as President of High Rider Capital Inc. until April 29, 2009. Dr. Verrico served as Secretary and Chief Executive Officer of Consolidated Ecoprogress Technology Inc from October 2002 to March 2004. Dr. Verrico has extensive experience as an investor in the junior capital markets providing both venture capital loans and a number of private placements. He serves as the Chairman of Sirona Biochem Corp. and has been its Director since September 19, 2006. He served as Director of Consolidated Ecoprogress Technology Inc from October 2002 to March 2004. Dr. Verrico obtained his medical degree from the University of Toronto in 1985 and has been a Member of the College of Physicians and Surgeons of British Columbia since July 1986.

CEO Compensation
  • Howard's compensation has been consistent with company performance over the past year.
  • Howard's remuneration is about average for companies of similar size in Canada.
Management Team Tenure

Average tenure of the Sirona Biochem management team in years:

7.1
Average Tenure
  • The average tenure for the Sirona Biochem management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Howard Verrico

TITLE
Founder
COMPENSATION
CA$144K
AGE
57
TENURE
4.8 yrs

Christopher Hopton

TITLE
CFO & Director
COMPENSATION
CA$132K
AGE
52
TENURE
10 yrs

Géraldine Deliencourt-Godefroy

TITLE
Chief Scientific Officer & Director
COMPENSATION
CA$200K

Michelle Seltenrich

TITLE
Vice President of Operations

Brett Premack

TITLE
Scientific Consultant
TENURE
7.1 yrs
Board of Directors Tenure

Average tenure and age of the Sirona Biochem board of directors in years:

8.8
Average Tenure
53.5
Average Age
  • The tenure for the Sirona Biochem board of directors is about average.
Board of Directors

Christopher Hopton

TITLE
CFO & Director
COMPENSATION
CA$132K
AGE
52
TENURE
8.3 yrs

Géraldine Deliencourt-Godefroy

TITLE
Chief Scientific Officer & Director
COMPENSATION
CA$200K
TENURE
8.1 yrs

Alex Marazzi

TITLE
Independent Director
AGE
55
TENURE
12.5 yrs

Howard Verrico

TITLE
Founder
COMPENSATION
CA$144K
AGE
57

Michael Walker

TITLE
Member of the Scientific Advisory Board
TENURE
9.4 yrs

Denis Richard

TITLE
Member of the Scientific Advisory Board
TENURE
9.4 yrs

Bruce Verchere

TITLE
Member of the Scientific Advisory Board
TENURE
9.4 yrs

Casper Bych

TITLE
Independent Director
AGE
46
TENURE
3.8 yrs

Caigan Du

TITLE
Member of Scientific Advisory Board
TENURE
3 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Sirona Biochem insiders in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (CA$) Value (CA$)
04. Mar 19 Buy Christopher Hopton Individual 27. Feb 19 27. Feb 19 350,000 CA$0.10 CA$35,000
04. Mar 19 Buy Howard Verrico Individual 27. Feb 19 27. Feb 19 960,000 CA$0.10 CA$96,000
05. Mar 19 Sell Howard Verrico Individual 22. Feb 19 22. Feb 19 -460,000 CA$0.11 CA$-50,600
X
Management checks
We assess Sirona Biochem's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Sirona Biochem has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

SBM News

Simply Wall St News

Who Are The Largest Shareholders In Sirona Biochem Corp (CVE:SBM)?

I am going to take a deep dive into Sirona Biochem Corp’s (CVE:SBM) most recent ownership structure, not a frequent subject of discussion among individual investors. … When it comes to ownership structure of a company, the impact has been observed in both the long-and short-term performance of shares. … The implications of these institutions’ actions can either benefit or hinder individual investors, so it is important to understand the ownership composition of your stock investment.

Simply Wall St -

Why Sirona Biochem Corp's (CVE:SBM) Investor Composition Impacts Your Returns

In this article, I'm going to take a look at Sirona Biochem Corp’s (TSXV:SBM) latest ownership structure, a non-fundamental factor which is important, but remains a less discussed subject among investors. … See our latest analysis for Sirona Biochem TSXV:SBM Ownership_summary Apr 27th 18 Institutional Ownership Due to the big order sizes of institutional investors, a company's shares can experience large, one-sided momentum, driven by high volume of shares removed from, or injected into, the market. … Next Steps: With a low level of institutional ownership, investors in SBM need not worry about non-fundamental factors such as ownership structure causing large impact on stock prices.

Simply Wall St -

Want To Invest In Sirona Biochem Corp (CVE:SBM)? Here's How It Performed Lately

Measuring Sirona Biochem Corp's (TSXV:SBM) track record of past performance is a useful exercise for investors. … View our latest analysis for Sirona Biochem Commentary On SBM's Past Performance I look at the ‘latest twelve-month’ data, which annualizes the latest 6-month earnings release, or some times, the latest annual report is already the most recent financial data. … For Sirona Biochem, its most recent earnings (trailing twelve month) is -CA$4.01M, which, in comparison to the previous year's figure, has become more negative.

Simply Wall St -

Why Sirona Biochem Corp's (CVE:SBM) CEO Pay Check Matters To You

Profitability of a company is a strong indication of SBM's ability to generate returns on shareholders' funds through corporate activities. … In the situation of negative earnings, the company may be incurring a period of reinvestment and growth, or it can be a sign of some headwind. … Normally I would use earnings and market cap to account for variations in performance, however, SBM's negative earnings lower the usefulness of my formula.

Simply Wall St -

Can Sirona Biochem Corp (CVE:SBM) Improve Your Portfolio Returns?

A widely-used metric to measure a stock's market risk is beta, and the broad market index represents a beta value of one. … Based on this beta value, SBM appears to be a stock that an investor with a high-beta portfolio would look for to reduce risk exposure to the market. … How SBM's assets could affect its beta An asset-heavy company tends to have a higher beta because the risk associated with running fixed assets during a downturn is highly expensive.

Simply Wall St -

Has Sirona Biochem Corp's (CVE:SBM) Improved Earnings Growth In Recent Times?

When Sirona Biochem Corp (TSXV:SBM) released its most recent earnings update (31 July 2017), I wanted to understand how these figures stacked up against its past performance. … The two benchmarks I used were Sirona Biochem's average earnings over the past couple of years, and its industry performance. … Sirona Biochem's latest twelve-month earnings -CA$2.8M, which, relative to last year’s level, has become less negative.

Simply Wall St -

Are You Backing The Right Horse With Sirona Biochem Corp (TSXV:SBM)?

Healthcare analysts are forecasting for the entire industry, negative growth in the upcoming year , and an overall negative growth rate in the next couple of years. … Unsuprisingly, this is below the growth rate of the Canadian stock market as a whole. … TSXV:SBM PE PEG Gauge Nov 9th 17 Biotech companies are typically trading at a PE of 17x, relatively similar to the rest of the Canadian stock market PE of 17x.

Simply Wall St -

What Does Sirona Biochem Corp's (TSXV:SBM) Ownership Structure Look Like?

This size of ownership gives retail investors collective power in deciding on major policy decisions such as executive compensation, appointment of directors and acquisitions of businesses. … Such level of ownership gives retail investors the power to sway key policy decisions such as board composition, executive compensation, and potential acquisitions. … With a low level of institutional ownership, investors in SBM need not worry about non-fundamental factors such as ownership structure causing large impact on stock prices.

Simply Wall St -

SBM Company Info

Description

Sirona Biochem Corp. operates as a cosmetic ingredient and drug discovery company in Canada and France. The company develops programs in three areas, including diabetes, anti-inflammatories, and anti-infectives for therapeutics; anti-aging and depigmenting agents in cosmeceuticals; and biological ingredients, such as inducers and adjuvants for the biological development and preservation. It develops a sodium glucose co-transporter inhibitor for the treatment of diabetes, as well as cosmetic skin lightening agents and compounds. The company was formerly known as High Rider Capital Inc. and changed its name to Sirona Biochem Corp. in May 2009. Sirona Biochem Corp. was incorporated in 2006 and is headquartered in Vancouver, Canada.

Details
Name: Sirona Biochem Corp.
SBM
Exchange: TSXV
Founded: 2006
CA$38,719,391
198,560,982
Website: http://www.sironabiochem.com
Address: Sirona Biochem Corp.
889 West Pender Street,
Suite 605,
Vancouver,
British Columbia, V6C 3B2,
Canada
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
TSXV SBM Common Shares TSX Venture Exchange CA CAD 05. May 2009
OTCPK SRBC.F Common Shares Pink Sheets LLC US USD 05. May 2009
DB ZSB Common Shares Deutsche Boerse AG DE EUR 05. May 2009
Number of employees
Current staff
Staff numbers
0
Sirona Biochem employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/19 00:18
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2017/03/01
Last earnings filing: 2019/03/28
Last earnings reported: 2019/01/31
Last annual earnings reported: 2018/10/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.